RxDoctor Payments Data

Sandra Kuniyoshi, MD

Neurology · Phoenix, AZNPI 1265590855

Payments from drug & device makers

$842in general payments, 2019–2025

Across 49 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MDD US Operations, LLC$184
  • AbbVie$122
  • Amneal Pharmaceuticals LLC$77
  • Sunovion Pharmaceuticals Inc.$63
  • Acorda Therapeutics, Inc$56
  • Portola Pharmaceuticals, LLC$53
  • plus $287 from 13 others

What the payments were for

  • Speaking & faculty fees$567%
  • Food & beverage$78593%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$842 in reported general payments places this provider in the 35th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$109,743
Medicare patients
300
Services billed
1,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate21$169,000
RytaryCarbidopa/Levodopa69$75,087
Aimovig AutoinjectorErenumab-Aooe60$52,400
Nurtec OdtRimegepant Sulfate33$37,134
Rasagiline Mesylate76$17,950
UbrelvyUbrogepant17$17,573
Emgality PenGalcanezumab-Gnlm21$14,863
BotoxOnabotulinumtoxina13$14,013
Carbidopa-LevodopaCarbidopa/Levodopa251$9,562
AmantadineAmantadine Hcl41$2,140
Gabapentin57$1,430
Propranolol Hcl49$951
Pramipexole DihydrochloridePramipexole Di-Hcl24$919
Donepezil Hcl41$544
Topiramate50$530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$17$169,00021 claims
Amneal Pharmaceuticals LLCRytary$77$75,08769 claims
AbbVieUbrelvy, Botox$122$31,58630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 388 neurology providers in Arizona.

Other neurology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →